Once Weekly Selinexor, Carfilzomib and Dexamethasone in Carfilzomib Non-refractory Multiple Myeloma Patients
Overview
Authors
Affiliations
Background: Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).
Methods: The safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m) + dexamethasone (40 mg) (XKd) once weekly (QW) was evaluated in patients with relapsed refractory MM (RRMM) not refractory to carfilzomib.
Results: Thirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m, and dexamethasone 40 mg, all QW. The overall response rate was 78% including 14 (44%) ≥ very good partial responses. Median progression-free survival was 15 months.
Conclusions: Weekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.
Tan C, Kacerek D, Kampirapawong N, Godara A, Chaiyakunapruk N Cancer Med. 2025; 14(5):e70585.
PMID: 40052837 PMC: 11887125. DOI: 10.1002/cam4.70585.
Costa L, Banerjee R, Mian H, Weisel K, Bal S, Derman B Leukemia. 2025; 39(3):543-554.
PMID: 39870767 PMC: 11879857. DOI: 10.1038/s41375-024-02482-6.
Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.
Aumann W, Kazi R, Harrington A, Wechsler D Oncol Rev. 2024; 18:1427497.
PMID: 39161560 PMC: 11330842. DOI: 10.3389/or.2024.1427497.
Schutt J, Brinkert K, Plis A, Schenk T, Brioli A Cancer Drug Resist. 2024; 7:26.
PMID: 39050883 PMC: 11267153. DOI: 10.20517/cdr.2024.39.
White D, Schiller G, Madan S, Lentzsch S, Chubar E, Lavi N Front Oncol. 2024; 14:1352281.
PMID: 38826786 PMC: 11140414. DOI: 10.3389/fonc.2024.1352281.